move top
컨텐츠 바로가기

HOME Research & Development Research Status

Research Status

  • A robust and well-balanced pipeline to address unmet medical needs in Anesthesia, Oncology, Pain and Other Diseases

    Last updated --

    • Pipeline Indication Discovery Pre-clinical Clinical Phase Phase 1 Phase 2 Phase 3 Marketed
    • HNP-2001 (Remimazolam)
      Partnered with Paion AG, Germany       General anesthesia

      Procedural Sedation



    • BOLD-100
      Partnered with Bold Therapeutics, Canada       Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma, TNBC
    • HNP-2006 Contrast Medium: MRI
    • GI System GERD
    • Pain Management Neuropathic Pain

      Chronic Pain

      Post-operative Pain




  • Safe MRI contrast media
    that overcomes the limitations
    of conventional contrast media1

    What is a contrast agent?1, 4

    Contrast agent is a medicine used to improve the contrast of diagnostic images by being injected into the human body. MRI contrast media enhances the accuracy and precision of MRI imaging and diagnosis. Currently, gadolinium (Gd)-based low molecular contrast media occupies the entire MRI contrast media market, and HNP-2006 is also this kind of agent.


    Gadolinium contrast agent2, 4

    Gadolinium contrast agents need to have thermodynamic stability, water solubility, paramagnetism and should include a multidentate structure that can form stable complexes with Gd (III) relaxation. What should be considered in the development of MRI contrast agents is that there should be no chemical activity of the compound itself, and that a well-designed multi-coordinating ligand should be developed so that gadolinium ions are not liberated systemically. In addition, after diagnosis is completed, it should be completely excreted out of the body to lower accumulation of gadolinium ions. These multicomponent complexes signal by combining with at least one molecule of water to promote relaxation of the water proton.

    Gadolinium2, 4

    Gadolinium (Gd) is a typical paramagnetic material used in MRI contrast media. When administered in the human body, it increases the MRI signal intensity by binding to water present in the body`s organ tissues and increases the relaxation rate of their hydrogen atom T1 (longitudinal magnetization). Each tissue will acquire images by differences in contrast due to different water content.

    Highly safety cyclic ligand technology
    • Chemical stability based on cyclic ligands
    • Easy excretion and elimination in vitro → Minimization of residue in vivo
    • Reduction of free gadolinium → Maximization of safety
    Gaining competitive edge through multi-functional contrast media
    • High efficiency paramagnetic composite with high contrast effect
    • Multi-functional MRI contrast media: high contrast effect on liver, blood vessel, cancer, and etc.
    • Gaining best-in-class competitiveness

    Best-in-class multi-functional MRI contrast media with enhanced safetyHNP - 2006

    Sources : IMS Health Data 2016